DESIO, Italy – The partnership between Gnosis and the US nutraceutical producer Xymogen is proving innovative!
Xymogen’s XaQuil™XR, finished oral dose product containing Gnosis’ Quatrefolic®, has been selected as a finalist of NutraIngredients Awards 2016 for the Finished Product of the Year – Medical Food category.
The NutraIngredients Awards identify and celebrate stellar achievement in the fields of ingredients and finished product innovation. Being recognized as finalists underlines the ambitious goals that Xymogen and Gnosis set when devoping XaQuil™ XR with Quatrefolic® for the benefit of depressed patients with suboptimal L-methylfolate levels.
XaQuil™ XR is an innovative, orally administered, extended release medical food, that offers the metabolically active form of folate, the (6S)-5-methyltetrahydrofolate (5-MTHF), in a new time-dependent formulation. It could be especially helpful to those people who cannot metabolize folic acid effectively.
Folate deficiency is common among depressed people, especially those who don’t respond to antidepressants: major depressive disorder (MDD) currently ranks as the fourth leading disease burden worldwide and is expected to become the second global disease burden in 2020 (Hyman 2006). XaQuil™ XR fulfills the emergent scientific data that is compelling psychiatrists to consider augmenting traditional antidepressants with a medical food L-methylfolate.
This year, more than 120 high-quality entries have been submitted to the judging panel and 33 stand-out products and ingredients have been chosen as finalists.
Winners of the NutraIngredients Awards will be announced on Wednesday 11th May during the annual gala dinner ceremony in Geneva, alongside Vitafoods Exhibition, where attendees, sponsors and industry professionals can network and celebrate new and significant developments with those that have successfully demonstrated their outstanding contributions to the industry.
We are all cheering for XaQuil™XR & Quatrefolic®!
About XaQuil™XR
XaQuil™XR is an innovative medical food formulated with Quatrefolic® where the release of the active ingredients is tightly controlled for an optimization of the blood levels of 5-MTHF and can be used as an adjunctive treatment for depression.
XaQuil™XR may constitute an effective, safe, and well tolerated medical food strategy for patients with major depressive disorder who have a partial response or no response to SSRIs (Selective Serotonin Reuptake Inhibitors).
In XaQuil™XR Quatrefolic® provides folate in the already biologically active form of 5-methyltetrahydrofolate, without any kind of metabolization. 5-MTHF can reach the systemic circulation and cross the blood-brain barrier, and enter straight the brain cell, for direct utilization in the folate cycle.
Gnosis and Xymogen have been working together to develop an unique extended release formulation in tablets with specific release profile of the active ingredient useful to increase the folate levels. The XaQuil™XR formulation allows a time dependent release of the 5-MTHF in the gastroenteric system, followed by a time-dependent release of the active in the plasma. Extended-release of 5-MTHF may be crucial in partial response or no response subjects to SSRIs because normalizes the blood folate level and maximizes efficacy of XaQuil™XR.
XaQuil™XR. extended-release coating technology is property of Gnosis S.p.A (International Application PCT/IB2014/065852).
About Xymogen
XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.
XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.
